Fulcrum Therapeutics Inc
NASDAQ:FULC
Fulcrum Therapeutics Inc
NASDAQ:FULC
Price:
8.56 USD
8.22%
Updated:
May 15, 2024
Fulcrum Therapeutics Inc
Selling, General & Administrative
|
Fulcrum Therapeutics Inc
Selling, General & Administrative Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
Selling, General & Administrative
-$41.7m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Selling, General & Administrative
-$21.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Selling, General & Administrative
-$7.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Selling, General & Administrative
-$14.5B
|
CAGR 3-Years
-76%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Selling, General & Administrative
-$10.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Selling, General & Administrative
-$7.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
See Also
What is Fulcrum Therapeutics Inc's Selling, General & Administrative?
Selling, General & Administrative
-41.7m
USD
-41.7m
USD
Based on the financial report for Dec 31, 2023, Fulcrum Therapeutics Inc's Selling, General & Administrative amounts to -41.7m USD.
What is Fulcrum Therapeutics Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-38%
-38%
Over the last year, the Selling, General & Administrative growth was 0%. The average annual Selling, General & Administrative growth rates for Fulcrum Therapeutics Inc have been -25% over the past three years , -38% over the past five years .
You don't have any saved screeners yet
